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Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that is a humoral component
of the innate immune system. It interacts with pathogenic moieties, infected and dying
host cells and facilitates their removal through activation of appropriate innate and adaptive
mechanisms. PTX3 is secreted by a diverse variety of cells, ranging from immune cells to
structural cells, in response to Toll like receptor (TLR) engagement, inflammatory stimuli,
and physical and chemical stress. Further, PTX3 plays an essential role in female fertility as
it facilitates the organization of extracellular matrix in the cumulus oophorus. Such activity
is also implicated in post-inflammation tissue repair. PTX3 is a multifunctional protein and
plays a non-redundant role in providing immunity against potential immunological dangers.
Thus, we assessed its role in lung immunity, as lungs are at a constant risk of infections
and tissue damage that is attributable to perpetual exposure to foreign agents.
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INTRODUCTION
Pentraxins are a superfamily of evolutionarily conserved, specific
pattern recognition proteins that play a salient role in the innate
immune system. Based on size, these multifunctional proteins are
divided into long and short pentraxins. Long pentraxins include
the prototypic pentraxin 3 (PTX3), the recently identified PTX4,
and neuronal pentraxins 1 (NP1) and NP2 whereas short pen-
traxins consist of C-reactive protein (CRP) and serum amyloid P
(SAP) (Gewurz et al., 1995; Garlanda et al., 2005).
Phylogenetic analysis has demonstrated conservation of short
and long pentraxins in human, mouse, rat, opossum, chicken,
and some lower vertebrates (Martinez de la Torre et al., 2010).
Although all pentraxins evolve from a common ancestor, PTX3
alone forms a separate cluster and seems to originate directly from
the common ancestral pentraxin very early in evolution (Martinez
de la Torre et al., 2010).
Pentraxin 3 has been identified as biomarker of several
immunopathological states and its relevance with the resolution
of infections and diseases has also been studied. In this review, we
detail the general structure, expression, and functions of PTX3.
Also discussed are current findings, which suggest an important
role of PTX3 in immunological states, particularly those that are
associated with the lungs.
PTX3 GENE STRUCTURE
The human and murine PTX3 gene is localized on chromosome
3 (q22–28) (Breviario et al., 1992). The PTX3 gene is organized
into three exons: the first and the second exons translate to the
leader peptide and N-terminal domain, respectively, whereas the
third exon which corresponds to second exon of short pentraxins,
encodes pentraxin domain (Breviario et al., 1992) (Figure 1). The
human and mouse PTX3 displays 92% amino acid conservation
and 82% of these amino acid residues are identical (Introna et al.,
1996; Garlanda et al., 2005). Significant homology between human
and mouse PTX3 suggests that murine studies can be extrapolated
to address human issues.
The human PTX3 promoter contains several potential cis act-
ing elements including an NF-kB site, binding sites for activator
protein 1 (AP-1),AP-2, specificity protein (Sp1), and gamma inter-
feron activation site (GAS) (Altmeyer et al., 1995) (Figure 1).
In addition to these elements, the murine PTX3 gene promoter
sequence also contains binding sites for homeodomain (Hox)-
1.3, and transcription factors belonging to Ets family. The mouse
PTX3 gene contains a 44-bp stretch of alternating CA residues
in its promoter region, which acts as an enhancer element. The
murine promoter region also contains multiple NF-IL-6 binding
sites while its human counterpart contain only one, which draws
particular attention on the role of NF-IL-6 in the regulation of
PTX3 expression (Darnell et al., 1994).
Unlike short pentraxins, the PTX3 promoter does not con-
tain a consensus site for hepatic nuclear factor-1 (HNF-1), which
accounts for the absence of its induction in liver (Darnell et al.,
1994). Although human and murine PTX3 protein is homologous,
the human promoter contains lesser transcriptional elements than
does the murine promoter, an effect that needs to be studied using
molecular and phylogenetic analysis.
PTX3 PROTEIN STRUCTURE
The name pentraxin is derived from the molecule’s pentagonal
structure, which consists of five subunits. It was initially thought
that PTX3 acquired a quaternary structure that is similar to short
pentraxins, which consists of five identical 23 kDa subunits held
together by noncovalent non-covalent interactions. However, the
amino acid residues at the protomer interface that are required
for pentameric structural formation in CRP, are not present in
PTX3 (Introna et al., 1996). PTX3, exists mainly as octamers
made from two tetramers and each subunit is held together
by covalent bonds (Bottazzi et al., 1997; Garlanda et al., 2002;
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FIGURE 1 | Molecular structure of PTX3 gene in human and
mouse. PTX3 gene is organized into promoter region and three exons:
the first exon encodes for leader peptide (17 amino acids) while the
second and the third exons encode for N- and C-terminal domains of
the protein (381 amino acids). Promoter region contains multiple
transcription binding sites.
Inforzato et al., 2008). PTX3 octamers show greater functional
activity as compared to tetrameric oligomers (Inforzato et al.,
2008).
The PTX3 protein structure, like that of other pentraxins
includes a pentraxin domain containing HxCxS/TWxS (where
x is any amino acid) at C terminus (Figure 1). Its C-terminal
domain consists of 203 amino acids, 57% of which are conserved
in the entire pentraxin superfamily and the unique N-terminal
domain consists of 178 amino acids (Agrawal et al., 2009). The
PTX3 C- and N-terminal domains evolved independently, which
explains why the C-terminal domain is widely conserved while
the N-terminal domain is not (Martinez de la Torre et al., 2010).
Mature PTX3 protein is approximately 40 kDa, but glycosylation
at Asn220 increases the molecular weight to 45 kDa (Garlanda
et al., 2005). Oligosaccharide moieties at Asn220 can be complex
or heterogenous sialic and fucosyl sugar moieties. Unique glyco-
sylation patterns are associated with different inflammatory cells
and inflammatory stimuli that induce PTX3 production (Inforzato
et al., 2006). Desialylation of PTX3 results in stronger binding
to C1q and activates the classical complement pathway to a siz-
able extent (Inforzato et al., 2006) (Table 1). The PTX3 protein
has two conserved cysteine residues at the C-terminus (Cys210
and Cys271) and seven other cysteine residues, which are exclu-
sive to PTX3: three at the N-terminus (Cys47, 49, and 103) and
four in the C-terminal region (Cys179, 317, 318, and 357). These
cysteine residues form a network of disulfide bonds that main-
tains the PTX3 oligomeric structure. Interchain Cys47–Cys47 and
Cys49–Cys49 bonds form dimers and these dimers are further
held together by Cys103–Cys103 bonds that maintain tetrameric
structures (Doni et al., 2006). These tetrameric structures are fur-
ther assembled into octamers by disulfide bonds between Cys317
and Cys318, which are located on exposed loops of different pro-
tomers (Inforzato et al., 2008). The PTX3 C-terminal domain
is formed by two antiparallel β sheets, stabilized by Cys210 and
271 and organized into a β-jelly roll topology (Pepys and Baltz,
1983; Goodman et al., 1996). Cys179 and 357 also form disulfide
bonds and seem to limit the flexibility of the N- and C-terminal
regions by linking them together (Inforzato et al., 2008). The
N-terminal region, however, is predicted to assume a coiled coil
conformation as it is made up of four alpha helices (Presta et al.,
2007).
Recently, Delneste and coworkers showed that the PTX3
N-terminal domain is susceptible to cleavage by proteases,
particularly neutrophil elastase and Aspergillus fumigatus pro-
teases (Hamon et al., 2013). The serine protease inhibitor
PMSF, antipain, and chymostatin were shown to inhibit A.
fumigatus proteases activity but its activity was unaffected by
aspartic-, metallo-, cysteine-, and aminopeptidase protease
inhibitors (Hamon et al., 2013). Proteolytic cleavage of PTX3 has
added an interesting aspect to the regulation of PTX3 expression
and function and a detailed analysis is necessary to validate this
phenomenon.
CELLULAR SOURCES OF PTX3
There is a growing body of evidence suggesting that PTX3 can
be produced by many cell types and induced by various different
stimuli (Breviario et al., 1992; Lee et al., 1993). It is due to this
reason that PTX3 is capable to serve multiple functions depend-
ing upon condition. It is interesting to note that regardless of the
source of its production (immune cells or structural cells), PTX3
plays a critical role in regulation of the humoral arm of innate
immunity (Lee et al., 1993).
IMMUNE CELLS
Lymphoid cells such as T cells, B cells, and NK cells do not express
PTX3. This highlights the significance of PTX3’s control on the
innate immune system (Deban et al., 2011). However, the action
of PTX3 is not limited to the innate immune system: PTX3 coor-
dinates with adaptive immune system and facilitates protection
against infections.
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Table 1 | Pentraxin 3 interacts with various ligands to mediate diverse function.
Ligand Role Characteristics of interaction Reference
1 P-selectin Inhibition of neutrophil migration C-terminal domain is required Deban et al. (2010)
Dependent on glycosylation pattern
2 C1q Complement activation C-terminal domain of PTX3 is required Inforzato et al. (2006), Baruah et al.
(2006)Desialylation of PTX3 favors interaction
Interaction is mediated through globular
head of C1q
Inhibitory effect when C1q is in fluid
phase
Calcium independent
3 Ficolins Complement activation Calcium dependent Ma et al. (2009), Gout et al. (2011)
Interaction mediates through
fibrinogen-like domain of ficolins
Glycosylation pattern in C-terminal domain
of PTX3 is a determining factor
4 Factor H Complement activation N- and C-terminal domains are required
for interaction
Deban et al. (2008)
Interaction is calcium dependent
Glycosylation of PTX3 stabilizes the
interaction
5 MBL Complement activation Mediated through collagen like domain of
MBL
Martin et al. (2009)
Interaction dependent on calcium
6 FyRs Opsonophagocytosis Moalli et al. (2010), Lu et al. (2008)
7 FGF-2/8b Anti-angiogenesis Interaction through N-terminal domain
(FGF-2)
Moalli et al. (2010), Lu et al. (2008),
Rusnati et al. (2004), Camozzi et al.
(2005, 2006)
8 TSG-6 Extracellular matrix deposition Interaction through N-terminal domain Salustri et al. (2004), Maina et al.
(2009)
9 Galactomannan
(component of conidia)
Disposal of conidia Garlanda et al. (2002)
10 OmpA (Klebsiella
pneumoniae)
Activation of immune response against
Klebsiella (complement activation)
High affinity interaction
Calcium dependent
Cotena et al. (2007), Jeannin et al.
(2005)
11 Hemagglutinin Inhibition of viral attachment to host
cells
Calcium independent
Sialic moiety on PTX3 and mannose on
hemagglutinin are involved in interaction
Bozza et al. (2006), Reading et al.
(2008)
This table shows list of PTX3 ligands and role and characteristic features of their interaction.
Dendritic cells
Among cells of immune system, myeloid cells, and
especially dendritic cells (DCs), are the main source of
PTX3 (Introna et al., 1996). An intricate network, as
demonstrated by Doni et al. (2006) regulates its expres-
sion in myeloid DCs upon stimulation with the Toll like
receptor (TLR) ligands, CD40L, IL-10, and IL-1β. How-
ever, no such effect was observed in plasmacytoid DCs.
Macrophages also express PTX3. Macrophages from PTX3
overexpressing mice show an augmented phagocytic response
to zymosan and Paracoccidioides brasiliensis (Deban et al.,
2011).
Neutrophils
Neutrophils are the only granular cells reported to release
preformed PTX3 in response to TLR agonists and microor-
ganisms. PTX3 exists as a monomer in “ready to release”
myeloperoxidase (MPO) negative granules containing lactoferrin
and lactoferrin/gelatinase and assembles into multimers upon
release. When neutrophils are activated in response to inflam-
matory stimulation, they release 25% of their PTX3. Part of the
released PTX3 remains associated with neutrophil extracellular
traps (NETs), which interacts with certain components of NETs
(Jaillon et al., 2007; Daigo et al., 2012). Neutrophils are among the
first cells to defend against foreign pathogens and the immediate
www.frontiersin.org May 2013 | Volume 4 | Article 127 | 3
Balhara et al. Role of PTX3 in immunopathological states of the lungs
release of PTX3 by these cells may be indicative of its importance
in innate immunity.
STRUCTURAL CELLS AND OTHER CELLS
Adipocytes
Pentraxin 3 is induced by TNF in adipocytes (Abderrahim-
Ferkoune et al., 2003). Preadipocytes also showed PTX3 expres-
sion, which decreases upon differentiation to adipocytes. In light
of differential PTX3 expression in different differentiation stages
of adipocytes, function of PTX3 in this process was found irrel-
evant. Additionally, a greater level of PTX3 mRNA was observed
in adipose tissue of obese and obese diabetic mice as compared
to WT mice. Although authors suggested this expression resulted
from adipocytes, examination of cell-specific PTX3 production
in these tissues is requisite (Abderrahim-Ferkoune et al., 2003).
Altogether, more studies are required to determine the functional
outcome of the role of PTX3 during differentiation and also in
obese condition.
Cardiomyocytes
Pentraxin 3 is constitutively expressed in the human heart by car-
diomyocytes. (Peri et al., 2000). However dying and necrotic cells
release it in large quantities, contributing to its increased level
in the blood of patients with acute myocardial infarction (AMI)
(Peri et al., 2000). Although its exact role in healthy myocytes is
not well understood, it is generally used as an indicator of tissue
damage in AMI (Peri et al., 2000). Heart myocytes experience con-
stant physical stress. Whether such a stress is associated with PTX3
constitutive expression is not clear. PTX3 protein expression was
shown to be increased in murine cardiomyocytes after transverse
aortic constriction and H2O2 (Suzuki et al., 2003).
Endothelial cells
In atherosclerosis, high-density lipoprotein (HDL) induces the
expression of PTX3 by activating a PI3K/Akt-dependent pathway
in endothelial cells. Here PTX3 is suggested to manifest an anti-
inflammatory and protective function (Norata et al., 2008). PTX3
is also induced by Lysophosphatidic acid (LPA), the lipid compo-
nent of oxidized low-density lipoproteins (oxLDL) through the
activation of NF-kB and is suggested to have a proatherogenic
function (Gustin et al., 2008). These contradictory observations
advocate the need of a unifying study to unveil the exact role of
PTX3 in the development or resolution of atherosclerosis.
Epithelial cells
Alveolar epithelial cells (ECs) produce PTX3 upon mechanical
stretch in vitro (Wu et al., 2009). LPS and TNF also induce pro-
duction of PTX3 in ECs (Han et al., 2005). Human proximal renal
tubular ECs constitutively express PTX3 mRNA, which is further
upregulated by IL-1β, TNF, IL-17, and CD40L. IL-6 and IL-4 have
no effect on PTX3 expression whereas GM-CSF was shown to
diminish the effect of IL-1β (Nauta et al., 2005).
Chondrocytes
Enhanced expression of PTX3 was observed in synoviocytes and in
synovial fluid from patients with rheumatoid arthritis (RA). IL-1β
and oncostatin M (OSM) synergistically induce PTX3 expression
in chondrocytes of the synovium (Barksby et al., 2006; Andreas
et al., 2009) but whether or not PTX3 is involved in cartilage repair
or degradation is largely unexplored. Expression of PTX3 in RA
synoviocyte is however unaffected by TNF or IL-1β but is down
regulated by TGF-β and IFN gamma (Luchetti et al., 2000).
Brain cells
Although PTX3 and neuronal pentraxins belongs to the same fam-
ily, expression of former is generally not observed in the brain. It
is, however induced by inflammatory stimuli such as LPS, TNF,
and IL-1 in granule cells, presumptive glial cells in the white mat-
ter (corpus callosum, fimbria), meningeal pia mater, and dentate
gyrus hilus (Polentarutti et al., 2000; Ravizza et al., 2001).
PTX3 IN LUNG DISEASES
The level of circulating PTX3 is low in healthy human condi-
tion (<2 ng/ml), but a rapid increase is observed in inflammatory
conditions starting from very early stages. Due to its precocious
appearance in various clinical conditions, research has focused
on investigating whether PTX3 can be used as an index of sys-
temic inflammatory activation. Another major reason suggestive
of its suitability as a marker of severity of diseases like tuberculosis
particularly in parasite endemic regions is the fact that its plasma
level is unaffected by helminthic infections. There are several stud-
ies described in following sections, which demonstrate association
between different diseased states and higher levels of PTX3.
Chronic obstructive pulmonary disorder
Chronic obstructive pulmonary disorder (COPD) is character-
ized by an irreversible airflow limitation that is associated with an
abnormal inflammatory response in the lungs. The status of PTX3
in COPD patients is controversial. According to Van Pottelberge
et al. (2012), no difference was observed in the levels of PTX3 in
serum, sputum, pulmonary arteries, and alveolar space of COPD
patients compared to healthy donors. However they claimed
reduction in PTX3 positivity in lung sections obtained from mod-
erate and severe COPD patients as compared to mild patients
and healthy subjects (Van Pottelberge et al., 2012). Delneste and
coworkers showed an increase in PTX3 level in serum and sputum
of COPD patients compared to healthy people (Hamon et al.,
2013). However, further investigation is required to determine
whether this discrepancy in observation is due to the proteolytic
cleavage of PTX3 in subjects participating in the former study
or to the subjects’ demographic characteristics. Among various
causative agents, cigarette smoke (CS) is a major cause of chronic
COPD (Pauwels et al., 2010). Subacute and chronic exposure to CS
augments PTX3 levels in the lung tissue of a murine COPD model,
particularly in the pulmonary veins and venules. This upregulation
was found to be dependent on the IL-1 pathway. Further, a criti-
cal role of PTX3 in the regulation of COPD-induced pulmonary
inflammation, emphysema, and body weight changes was ruled
out in this study because no significant difference was observed
between CS exposed PTX3 knock-out (KO) and WT mice (Pauwels
et al., 2010).
Asthma
Pentraxin 3 expression is also found to be associated with the
pathology of asthma. In human biopsy samples collected from
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healthy and asthmatic subjects, our lab has found an enhanced
expression of PTX3 in airway epithelium, infiltrating inflam-
matory cells, and airway smooth muscle bundles of asthmatic
samples compared to their healthy counterparts. Interestingly, we
did not observe any difference in PTX3 positivity between the
lung sections from mild, moderate, and severe asthmatic. Stud-
ies examining the role of potential proteolytic cleavage of PTX3
would provide detailed insight into the regulation of PTX3 expres-
sion in asthma. We have also investigated the production of PTX3
in primary human airway smooth muscle cells (HASMCs) and
ECs in vitro and found that HASMCs produce greater PTX3 as
compared to ECs. Further, TNF and IL-1β were found to signif-
icantly upregulate its expression in HASMCs, but the effect of
Th2, Th1, and Th17 cytokines was found to be negligible. PTX3
induces the production of eotaxin-1/CCL-11. Further, stimula-
tion of HASMCs with PTX3 is found to inhibit fibroblast growth
factor-2 (FGF-2) mediated migration (Zhang et al., 2012).
Lung carcinoma
Initially, PTX3 was suggested to be useful only as a marker of lung
carcinoma based on studies performed on lung cancer cell lines
(Planque et al., 2009) but more recent studies have determined
that PTX3 could be used as a serum biomarker for the diagnosis
and prognosis of lung carcinoma. Its suitability is overwhelming
due to its ability to differentiate between cancer patients and non-
cancer patients who are at higher risk of developing lung cancer
(Diamandis et al., 2011).
Acute lung injury
Acute lung injury (ALI) and Acute Respiratory Distress Syn-
drome (ARDS) ALI/ARDS is characterized by injury associated
with activation of the innate immune system in lungs. PTX3 is
widely accepted as a marker of ALI because it is found in patients
diagnosed with ALI within 24 h (He et al., 2007) and is closely asso-
ciated with the severity of the disease. Concurrent infiltration of
neutrophils, enhanced nitric oxide production, augmented expres-
sion, and function of tissue factor (TF) in lungs was observed
in this pathological state (Lee et al., 1990, 1993, 1994). Conse-
quently, it was suggested that a high level of PTX3 activates the local
innate immune system, which was thought to serve a protective role
against insults to which the lung tissue is exposed. LPS-induced
ALI was investigated in PTX3 KO mice and the authors found
that PTX3 KO mice were more susceptible to tissue damage as
a result to LPS exposure compared to wild type mice (Okutani
et al., 2007). In addition, PTX3 knock-in mice were observed to
be better protected from LPS-induced endotoxemia (Dias et al.,
2001). In an ALI model, PTX3 levels and the disease severity were
found to be regulated by TF and TF, in turn, is induced by PTX3
(Han et al., 2011). Additional detailing of mechanisms in PTX3
KO mice other than the involvement of TF, which rendered them
susceptible to ALI would shed more light on the role of PTX3.
PTX3 AND LUNG INFECTIONS
Pseudomonas aeruginosa infection
Pseudomonas aeruginosa is one of the prominent bacteria colo-
nizing the lungs and causing chronic lung infections observed in
Cystic Fibrosis (CF) patients. In humans, the PTX3 level increases
in the serum of CF patients compared to healthy subjects (Hamon
et al., 2013). Colonization of P. aeruginosa in CF patients is found
to be positively associated with two intronic SNPs (rs1840680 and
rs2305619) and one exonic SNP (rs3816527) in the PTX3 gene
(Chiarini et al., 2010). In mouse, protective role of PTX3 was
observed, as PTX3 KO mice are more susceptible to P. aerugi-
nosa infection. Recombinant PTX3 facilitates the clearance of this
pathogen by promoting an appropriate immune response in the
lungs of PTX3 KO mice. This effect was demonstrated to be depen-
dent on C3 and Fcγ and independent of C1q (Moalli et al., 2011).
The mechanism by which this protective role is mediated through
the complement system is described elsewhere in this review.
Intraperitoneally administered PTX3 decreased the concentration
of inflammatory mediators such as IL-1ββ, IL-17, CCL-2/MCP-1,
CXCL1/KC, and CXCL2/MIP-2 in P. aeroginosa infected CF mice
as compared to untreated CF mice. PTX3 treatment also decreased
the infiltration of neutrophils and increased the percentage of
monocytes in bronchoalveolar lavage fluid (BALF) from CF mice.
Improvement in vascular leakage was also observed in CF mice
upon PTX3 treatment (Paroni et al., 2012).
Aspergillosis
Aspergillus fumigatus is an opportunistic pathogen mainly infect-
ing immunodeficient patients. In Invasive Pulmonary Aspergillo-
sis (IPA), conidia of A. fumigatus induce the PTX3 secretion in
the lungs which in turn recognizes and binds to the galactoman-
nan moieties on the conidia and facilitates its phagocytosis by
macrophages (Garlanda et al., 2002). Association of PTX3 with
C3b and the resulting activation of C11b through FcγR are also
involved in this process (Moalli et al., 2010). Additionally, PTX3
is also related to the amplification of the antifungal response by
inducing the release of MCP-1/CCL-2 in mononuclear phago-
cytes thus promoting homing of monocytes to the lung tissue to
aid in clearing the pathogen (Garlanda et al., 2002). PTX3 also
activates the lectin complement pathway by binding to ficolin-
L-bound Aspergillus conidia in an attempt to clear the infection
(Moalli et al., 2010). Another mode of pathogen clearance is by
the activation of DCs and subsequent induction of a Th1 response
(Garlanda et al., 2002). In PTX3 KO mice, susceptibility to IPA
was associated with increased levels of IL-4 (a Th2 cytokine)
and decreased amounts of IFN gamma and IL-2 (Th1 cytokine).
Pulmonary A. fumigatus infection is a major concern in immuno-
compromised patients, particularly in bone marrow transplant
patients and PTX3 allows a rapid recovery of myeloid and lym-
phoid cells into the lung tissue, which helps to accelerate the
reconstitution of the patients’ immunity (Gaziano et al., 2004).
Since cytomegalovirus (CMV) infections can also result in such
an immuno-compromised state, PTX3 can resolve super infection
by A. fumigatus even in a CMV-infected state (Bozza et al., 2006).
Pentraxin 3 shows differential binding patterns. It does not
bind with hyphae but rather it binds only with the A. fumiga-
tus, A. flavus, and A. niger conidia. However, interaction between
PTX3 and fungal strains other than these such as Candida albicans
is not observed (Garlanda et al., 2002). Thus direct action on C.
albicans is not possible, but PTX3 can resolve Candida infection
through binding with mannose binding lectin (MBL) (Table 1)
and the subsequent recruitment of C1q and activation of classical
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complement cascade (Ma et al., 2009). The precise mechanism
of C. albicans clearance from the lungs by PTX3 requires further
investigation.
Tuberculosis
Plasma level of PTX3 is found to be correlated with the clinical
severity of tuberculosis and therefore is seen as an appropriate indi-
cator of the disease stage (Azzurri et al., 2005). PTX3 level declines
with the success of therapeutic treatment against tuberculosis but
increases again when treatment fails. This is also suggestive of the
suitability of PTX3 as a tool to follow up the efficacy of treat-
ment (Azzurri et al., 2005). Analysis of lung samples from human
subjects determined that exposure to BCG vaccine leads to an
increase in level of PTX3 (Aranday Cortes et al., 2010). This sug-
gests that expression of PTX3 could be a protective mechanism
and is not just a marker of the diseased state. One mechanism
to confer immuno-protection may be mediated by monocytes
that are induced to express PTX3 by the mycobacterial compo-
nent (Mycobacterial lipoarabinomannan, LAM) (Vouret-Craviari
et al., 1997). In humans, susceptibility to Mycobacterium tuberculi
is also found to be positively associated with two intronic SNPs
(rs1840680 and rs2305619) in PTX3 gene (Olesen et al., 2007).
However some unanswered questions require further investiga-
tion, particularly, the mechanism of action of PTX3 on monocytes
and involvement of other cell types in this process. It would also
be worthwhile to determine any additional role for PTX3 plays
additional roles in context with tuberculosis and its associated
outcomes in the lungs.
Pneumonia
Klebsiella pneumoniae causes acute pulmonary infection in
immuno-compromised subjects and results in pneumonia. Like
other bacterial infections, PTX3 levels are found to be associated
with the disease progression. A study by Soares et al. (2006) and
Dias et al. (2001) determined that in PTX3 transgenic mice, high
inoculum of bacteria induces overt expression of PTX3, and cul-
minates in greater lethality. Very high levels of PTX3 inhibit neu-
trophil influx in the lungs due to inhibition of P-selectin (Deban
et al., 2010) and enhanced NO production and iNOS expression
(Soares et al., 2006). As a result of this, production of TNF was
found inhibited, resulting in greater bacteria count in lung tis-
sue (Soares et al., 2006). Since TNF induces PTX3 expression,
one explanation for reduced production of TNF in this infection
model could be a feedback mechanism to regulate PTX3 levels and
exacerbations that may result from its very high levels. However,
when PTX3 transgenic mice were infected with a smaller inocu-
lum, protective effects of PTX3 were conferred and was attributed
to enhanced TNF production, increased neutrophil infiltration to
lungs and decreased bacterial load in lungs and blood (Soares et al.,
2006). It is quite possible that such a protective effect is initiated by
a mechanism that involves PTX3 induction by [Outer membrane
protein A (OmpA) of K. pneumoniae] through TLR2, which in
turn binds OmpA (Table 1) and amplifies the activation of com-
plement cascade and promotes the opsonophagocytosis of OmpA
containing bacteria (Jeannin et al., 2005; Cotena et al., 2007). In
humans, a positive correlation is observed between plasma lev-
els of PTX3 and the severity of Community acquired pneumonia
(CAP) and that PTX3 concentration decreased upon treatment
with antibiotics. The PTX3 level was also found to be significantly
correlated with the length of the hospital stay for CAP patients
(Kao et al., 2012).
Cytomegalovirus infection
Cytomegalovirus is a herpes virus, present in the majority of the
general population. It exists in latent form even after the infection
is treated and may reactivate in an immunocompromised state
(Forbes, 1989). PTX3 not only provides protection at very early
stages of CMV infection, but also suppresses reactivation (Bozza
et al., 2006). PTX3 mediates its action by binding to hemagglu-
tinin (Table 1) on the surface of the virus and blocks its entry
into host cells, particularly DCs (Bozza et al., 2006). It can also
induce antiviral immunity through the activation of mDCs and
subsequent up regulation of appropriate T cells functions (Bozza
et al., 2006). Virus-bound PTX3 acts through TLR2, 3, and 4 and
induces the production of IFN gamma and IL-12 through the tran-
scription factor IRF3 in CD11b+ DCs C57BL/6 mice (Bozza et al.,
2006). mDCs themselves also secrete PTX3 upon exposure to viral
particles and maintains the loop of infection followed by immuno-
protection. Exogenous PTX3 is a promising potential therapeutic
agent against CMV infection, both alone (Bozza et al., 2006) and
in combination with Thymosin alpha-1 (Patent: use of thymosin
alpha-1, alone and in combination with PTX3 or Ganciclovir, for
the treatment of cytomegalovirus infection).
Influenza
The Influenza virus presents another serious challenge to the
respiratory tract because of its ability to mutate and create vir-
ulent variants as a mechanism to evade the host immune system.
Influenza viruses are RNA orthomyxoviruses, which infect ECs of
the respiratory tract (Matrosovich et al., 2004). A detailed study
by Reading et al. (2008) showed that like CMV, a sialic moiety of
PTX3 engages hemagglutinin of the influenza virus and hinders
attachment of the virus to host ECs. Inhibition of viral neu-
raminidase glycoprotein by PTX3 could be an additional strategy
to limit viral infection as it inhibits the release of newly formed
viral particles from the infected host cells (Kilbourne et al., 1968).
PTX3 also facilitates opsonization and clearance of infected cells.
PTX3 KO mice are more prone to influenza virus infection but
attained resistance when treated with exogenous PTX3 (Reading
et al., 2008).
Severe acute respiratory syndrome
Severe Acute Respiratory Syndrome (SARS) is caused by SARS
coronaviruses (SRAS-CoV) (Rota et al., 2003). The role of PTX3 is
discussed with respect to murine hepatitis virus (MHV) which is a
group 2 coronavirus that is closely related to its human counterpart
SARS-CoV (Rota et al., 2003; Han et al., 2012). MHV-1 infection
results in ALI in mice, similar to airways damage observed in the
lungs of SARS patients (De Albuquerque et al., 2006). MHV-1 air-
way infection induces PTX3 expression in the lungs. PTX3 bound
to MHV-1, reduced its infectivity and accelerated viral clearance.
Consequently, PTX3 KO mice showed greater pulmonary damage
as compared to their WT counterparts and the animals that were
treated with exogenous PTX3. In PTX3 KO mice, an early influx
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of neutrophils and macrophages into the lungs is found to exag-
gerate lung injury due to MHV-1 infection. Other inflammatory
determinants such as IL-6, MCP-1, and MIP-1b were found to
be enhanced in the PTX3 KO condition. However, production of
these inflammatory cytokines was reduced upon PTX3 treatment,
resulting in protection from airway damage (Han et al., 2012).
As a matter of caution, PTX3 is not a general mechanism to
guard against all pathogenic infections. Infection due to Listeria
monocytogenes and Salmonella typhimurium is neither controlled
nor exaggerated by PTX3 directly or indirectly. Similarly, PTX3
is unable to bind and mediate protection against some variants
of Influenza virus such as A/PR8/34 (HINI), H3N3, and type B
influenza viruses (Reading et al., 2008).
MECHANISM OF ACTION
Pentraxin 3 exerts diverse functions to provide immuno-
protection in multiple ways. It binds to the surface of pathogens
and apoptotic inflammatory cells and promotes their opsoniza-
tion and clearance early in the infection process. This role is
important to avoid inducing a deleterious hyper-inflammatory
state that could arise due to activation of the adaptive arm of the
immune response. Notably, although the N-terminal domain of
PTX3 is suggested to be required for pathogen binding, the full-
length protein is required for opsonizatio (Moalli et al., 2010).
Also PTX3 when bound to pathogenic components activates DCs,
which is instrumental in initiating an appropriate T cell response.
Another mechanism by which PTX3 initiates the thread of innate
immunity is by activating the complement cascade (Bozza et al.,
2006).
Complement pathway activation
A prototypical paradigm by which PTX3 activates the classical
complement pathway is by interacting with C1q (Table 1). PTX3
binds to the globular head of immobilized C1q through its C-
terminal domain, subsequently triggering the activation of the
downstream cascade. Glycosidic patterns on PTX3 significantly
contribute to its interaction with C1q (Inforzato et al., 2006).
Of note, when C1q is in solution, PTX3 inhibits the activa-
tion of complement pathway by blocking C1q interaction with
immunoglobulins or other agents (Baruah et al., 2006).
Eventually, the ability of PTX3 to resolve Aspergillus infection
in C1q KO mice but not in C3 KO mice indicated that PTX3
might also interact with other members of the complement family
to mediate its function. PTX3 amplifies C3b-mediated opsoniza-
tion and phagocytosis of Aspergillus conidia through inside-out
activation of CD11b in macrophages (Moalli et al., 2010). Conidia-
bound PTX3 binds to Factor H (Table 1) and promotes C3-
mediated activation of the alternate pathway (C3 is also deposited
on conidia) and killing of the pathogen. A similar mechanism is
employed to remove apoptotic cells which can be a potential cause
of unwanted inflammation (Deban et al., 2008). Factor H binds
to PTX3 at two sites: the PTX3 N-terminus acts as the primary
binding site and the glycosylated pentraxins domain acts as the
secondary binding site (Deban et al., 2008). While investigating
the role of PTX3 in the disposal of Aspergillus conidia, Moalli
et al. (2010) found that factor B of the alternate pathway is also
necessary for its activity.
Pathogens attempt to evade the immune system so as to infect
the host, in turn, activates multiple immune mechanisms to fight
against the infection. The work of Moalli et al. (2010) implicated
the role of all complement pathways in conidia opsonization. The
association of PTX3 with other complement components further
strengthens the suggestion. Along the same line, PTX3 was also
found to activate the lectin complement pathway, by interact-
ing with ficolins through their fibrinogen-like domain (Table 1)
(Martin et al., 2009). Ficolins recognize carbohydrate moieties
on pathogens and dying cells and provide immuno-protection by
activating the lectin complement pathway and prime the adaptive
immune response (Endo et al., 2011). Besides binding to ficolin-L,
PTX3 enhances complement activation resulting from ficolin-
L interaction with Aspergillus (Ma et al., 2009, 2011). However
the interaction between ficolin-L and PTX3 is critically affected
by polymorphism in ficolin-L gene causing a T236 amino acid
change in the fibrinogen-like domain (Ma et al., 2009). Similarly,
ficolin-M also interfaces with PTX3 (Ma et al., 2009). This may
be of even greater significance in this review because ficolin-M is
majorly produced and found in the lungs (Ma et al., 2009; Gout
et al., 2011). The ficolin-M tetramer binds to four PTX3 mole-
cules where a sialic moiety in an N-linked carbohydrate of the
C-terminal domain of later was found to be involved (Gout et al.,
2011).
PTX3 RECEPTOR AND LIGANDS
Because PTX3 acts on immune cells, playing a critical role in dri-
ving innate immunity against pathogens, it is possible that PTX3
might act through some unknown receptor. A study investigating
the binding properties of pentraxins with FcyRs determined that
PTX3 could recognize FcyRs (Lu et al., 2008) (Table 1). The func-
tional significance of such an interaction was later established in
an Aspergillus infection model (Moalli et al., 2010). The protective
effect of PTX3 against Aspergillus was found to be diminished in
the absence of FcγR. This interaction was suggested to activate
CD11b to induce opsonophagocytosis of the pathogen (Moalli
et al., 2010). With the diverse functions mediated by PTX3 at
the cellular level, it is likely that PTX3 may interact with addi-
tional unknown receptors, which could be the subject of further
investigation.
Pentraxin 3 binds to FGF-2 (Rusnati et al., 2004; Camozzi
et al., 2006) and fibroblast growth factor-8b (FGF-8b) (Leali
et al., 2011) (Table 1) and affects neovascularization by medi-
ating anti-angiogenic and anti-restenotic activity. FGF-2 induces
proliferation in vascular smooth muscle cells and endothelial cells,
which is inhibited by PTX3 (Rusnati et al., 2004; Camozzi et al.,
2005). PTX3 inhibits FGF-2 functions by physically interacting
through its N-terminal domain (Camozzi et al., 2006). TSG-6 also
interacts with PTX3 through the same domain and as a result, it
competes with FGF-2, thus abolishes the inhibitory effect of PTX3
on FGF-2-mediated angiogenesis (Leali et al., 2012). The associa-
tion between TSG-6 and PTX3 is extremely critical in orchestrating
ECM in cumulus oophorus, which is important for female fertility
(Salustri et al., 2004). Thus because PTX3 and TSG-6 were found
to be co-regulated in monocytes, macrophages and myeloid DCs,
their association was suggested to contribute to ECM remodeling
during inflammation (Maina et al., 2009).
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CONCLUDING REMARKS
Pentraxin 3, a unique member of the long pentraxins family, plays
an indispensable role in regulating our immune system against
pathogens, which are involved in several pulmonary pathologies.
Multiple mechanisms to recognize pathogens and to coordinate
with the activation of humoral and cell-mediated immunity might
explain why it is evolutionarily conserved from non-vertebrates
to complex and highly evolved vertebrates. Several disease and
infection models have been extremely useful in understanding the
role of PTX3 in normal and immuno-compromised disease states.
However, detailed and comprehensive investigations unveiling the
mechanisms by which PTX3 may modulate the immune system
are certainly needed. PTX3 is an essential factor in determining
female fertility, as it is instrumental in matrix deposition in cumu-
lus oophorus. Characterization of its role in other physiological
processes also requires further research.
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